Affibody publishes Annual Report 2023
Regulatory
April 19, 2024
Stockholm, Sweden, April 19, 2024. Affibody Medical AB (publ) today announced that the Annual Report for 2023 now is available at the company’s website, and as an attachment to this press release.
Overall, 2023 was a strong year for Affibody – among other things we received USD 15 million as the first milestone payment in the izokibep collaboration with ACELYRIN.
Looking ahead, one of the key steps we will take as an organization in the coming years is to build our commercialization footprint. This is driven by our retained right to commercialize izokibep in the Nordics. The first milestone payment marked the starting point of our work to prepare for a potential launch of the product in our home market.
We are firm believers in the competitiveness of izokibep, which this March was bolstered when the global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met its primary endpoint. Positive long-term data from the Phase 2b clinical trial in hidradenitis suppurativa (HS) were also announced. Izokibep continues with strong momentum, and we look forward to additional readouts from ongoing late-stage trials during the year, as well as the initiation of further Phase 3 studies.
We have also made significant progress in our radiopharmaceutical program, where our PET tracer ABY-025 has proven utility for diagnostic purposes in HER2-low cancers and our radiotherapy candidate ABY-271 is advancing towards the clinic.
In March 2023, we initiated a strategic collaboration with Chiesi to discover and develop novel Affibody® molecules for respiratory diseases.
//David Bejker, CEO Affibody
Financial summary 2023
Figures for 2022 within brackets.
- Net sales: SEK 191.8 M (226.6)
- Operating result: SEK -112.6 M (-144.0)
- Net result for the year: SEK -131.8 M (-161.8)
- Cash flow: SEK 89.7 M (-113.6)
- Cash and cash equivalents: SEK 126.2 M (45.2)
Read more in our Annual Report 2023 on www.affibody.com.